

Impact of pharmaceutical validation on prescribing errors in a Neonatal Intensive Care Unit.

Submission date 18/11/2023	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 21/11/2023	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 21/11/2023	Condition category Pregnancy and Childbirth	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Patients admitted to Neonatal Intensive Care Units (NICU) are up to eight times more at risk of medication errors than patients admitted to adult Intensive Care Units. Prescribing errors account for up to 74% of medication errors. Because of this, we have designed a project to improve the quality of care in order to reduce the number of prescription errors that reach the patient.

Who can participate?

This study is open to all newborns admitted to the intensive care unit.

What does the study involve?

We have designed a study to improve the quality of care in order to reduce medication errors in neonatal patients admitted to the intensive care unit. During this study, a clinical pharmacist will carry out a review of the treatments prescribed in the electronic prescription prior to the administration of the medication.

What are the possible benefits and risks of participating?

As this is a quality improvement project, patients can benefit from the improvement that a review of their treatment by a pharmacist can bring, without any risk.

Where is the study run from?

Hospital 12 de Octubre (Spain)

When is the study starting and how long is it expected to run for?

June 2021 to December 2022

Who is funding the study?

Hospital 12 de Octubre (Spain)

Who is the main contact?

Maria Dolores Canales, mcanales@salud.madrid.org

Contact information

Type(s)

Public, Scientific, Principal investigator

Contact name

Mrs Maria Dolores Canales

ORCID ID

<https://orcid.org/0000-0003-1192-2855>

Contact details

Calle de Salvador Allende, 34C

4b

Madrid

Spain

28054

+34 675091692

mcanales@salud.madrid.org

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

21/365

Study information

Scientific Title

Impact of pharmaceutical validation on prescribing errors in a Neonatal Intensive Care Unit.
Randomised and controlled study.

Study objectives

Pharmaceutical validation of medical prescriptions reduces medication errors reaching patients admitted to neonatal intensive care units

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 26/10/2021, Comité de Ética de la Investigación con medicamentos del Hospital Universitario 12 de Octubre (AV Cordoba SN, Madrid, 28054, Spain; +34 91 779 26 13; ceicdoc@h12o.es), ref: 21/365

Study design

Prospective randomized controlled study

Primary study design

Interventional

Study type(s)

Safety

Health condition(s) or problem(s) studied

Prevention of medical errors in newborns

Interventions

During the randomised phase, patients were assigned to the intervention or the control group at admission according to a simple randomisation using a web-based system (www.dcode.fr). Pharmaceutical validation of treatments was performed on a daily basis in the same way as in the pre-intervention phase for patients in the intervention group. For patients included in the control group, treatments were retrospectively reviewed at discharge from the NICU by the same pharmacist.

For all arms of the study, the follow-up time is for the duration of the patient's admission.

Intervention Type

Behavioural

Primary outcome(s)

Percentage of prescription errors detected by a clinical pharmacist in e-prescribing measured at the end of the study

Key secondary outcome(s)

Percentage of prescribing errors reaching the patient according to the nursing administration record measured at the end of the study

Completion date

31/12/2022

Eligibility

Key inclusion criteria

All patients born during the study period who were admitted to the NICU and stayed for at least 24 hours and with active pharmacological treatment

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Neonate

Lower age limit

0 days

Sex

All

Total final enrolment

240

Key exclusion criteria

Patients admitted without pharmacological treatment or less than 24h.

Date of first enrolment

01/09/2021

Date of final enrolment

30/06/2022

Locations**Countries of recruitment**

Spain

Study participating centre

Hospital 12 de Octubre

Av. Cordoba SN

Madrid

Spain

28041

Sponsor information**Organisation**

Hospital Universitario 12 De Octubre

ROR

<https://ror.org/00qyh5r35>

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Hospital Universitario 12 De Octubre

Results and Publications

Individual participant data (IPD) sharing plan

All data generated or analysed during this study will be included in the subsequent results publication

IPD sharing plan summary

Published as a supplement to the results publication